Leerink Partnrs Issues Negative Outlook for Geron Earnings

Geron Co. (NASDAQ:GERN) – Equities research analysts at Leerink Partnrs lowered their Q4 2025 earnings per share (EPS) estimates for shares of Geron in a research note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst F. Khurshid now anticipates that the biopharmaceutical company will post earnings of ($0.01) per share for the quarter, down from their previous forecast of $0.02. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share.

GERN has been the subject of a number of other reports. Needham & Company LLC cut their target price on Geron from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday. B. Riley downgraded shares of Geron from a “buy” rating to a “neutral” rating and cut their price target for the company from $3.50 to $2.00 in a report on Thursday. HC Wainwright downgraded shares of Geron from a “buy” rating to a “neutral” rating in a report on Wednesday. Scotiabank dropped their price target on Geron from $6.00 to $4.00 and set a “sector outperform” rating on the stock in a report on Thursday. Finally, Barclays reissued an “overweight” rating and set a $4.00 price objective (down from $9.00) on shares of Geron in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Geron presently has an average rating of “Moderate Buy” and a consensus target price of $5.68.

Geron Trading Up 1.1 %

Shares of NASDAQ:GERN opened at $1.76 on Thursday. The company has a 50 day moving average of $2.97 and a 200-day moving average of $3.80. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The firm has a market cap of $1.06 billion, a P/E ratio of -5.50 and a beta of 0.53. Geron has a twelve month low of $1.46 and a twelve month high of $5.34.

Geron (NASDAQ:GERN) last issued its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04). The business had revenue of $47.54 million for the quarter, compared to analysts’ expectations of $45.29 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%.

Institutional Investors Weigh In On Geron

Institutional investors have recently bought and sold shares of the business. Alternative Investment Advisors LLC. lifted its position in shares of Geron by 13.3% in the third quarter. Alternative Investment Advisors LLC. now owns 22,209 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 2,612 shares in the last quarter. Rovin Capital UT ADV increased its stake in Geron by 26.9% in the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 3,660 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Geron by 23.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,802 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 4,094 shares during the period. Xponance Inc. increased its stake in shares of Geron by 12.9% in the fourth quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 4,829 shares during the last quarter. Finally, US Bancorp DE raised its holdings in shares of Geron by 68.4% during the third quarter. US Bancorp DE now owns 18,296 shares of the biopharmaceutical company’s stock worth $83,000 after acquiring an additional 7,429 shares in the last quarter. 73.71% of the stock is currently owned by institutional investors and hedge funds.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.